{"id":27570,"date":"2012-02-22T12:25:37","date_gmt":"2012-02-22T17:25:37","guid":{"rendered":"http:\/\/www.hedgeco.net\/news\/?p=27570"},"modified":"2012-02-22T12:52:33","modified_gmt":"2012-02-22T17:52:33","slug":"hedge-funds-buying-into-hepatitis-c-treatments","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/02\/2012\/hedge-funds-buying-into-hepatitis-c-treatments.html","title":{"rendered":"Hedge Funds Buying into Hepatitis C Treatments"},"content":{"rendered":"<p>KapitallWire &#8211; Wall Street is clamoring to get in on the newest Hepatitis C drug stock rally. The move is largely a reaction to a series of successful developments from several new Hepatitis C treatments. The virus currently affects about 170 million people worldwide.<\/p>\n<p>The biopharmaceutical company Gilead Science (GILD) is now leading the race to develop a new all-oral therapy for Hepatitis C after acquiring Pharmasset for $11 billion in November.<\/p>\n<p><a href=\"http:\/\/wire.kapitall.com\/investment-idea\/hedge-funds-buying-into-hepatitis-c-treatments\/\" target=\"_blank\"><strong>Read Complete Article<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>KapitallWire &#8211; Wall Street is clamoring to get in on the newest Hepatitis C drug stock rally. The move is largely a reaction to a series of successful developments from several new Hepatitis C treatments. The virus currently affects about [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-27570","post","type-post","status-publish","format-standard","hentry","category-syndicated"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/27570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=27570"}],"version-history":[{"count":3,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/27570\/revisions"}],"predecessor-version":[{"id":27572,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/27570\/revisions\/27572"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=27570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=27570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=27570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}